Boao Lecheng : au cœur de la « zone franche médicale »

The Boao Lecheng International Medical Tourism Pilot Zone sits in Boao, Qionghai, Hainan, at the mouth of the Wanquan River, with a planned core area of about 20 square kilometres. Approved by the State Council in February 2013, it is China's only national-level pilot zone named for international medical tourism.

Access is easier than expected: about 15 minutes by car from Boao airport, roughly one hour by high-speed rail from Haikou Meilan airport plus a 20-minute drive, and about an hour by rail from Sanya Phoenix. Many patients fly into Haikou and out of Sanya, placing treatment and recovery near the coast.

The policy foundation is a set of four permits. The terms sound abstract; their meaning is concrete.

• Special medical permit: use of clinically urgent drugs and devices already approved abroad but not yet registered in China.
• Special research permit: front-line medical technology research and clinical real-world data applications.
• Special operating permit: social capital, including foreign capital, may establish medical institutions under the rules.
• Special exchange permit: international medical conferences and short-term practice by foreign physicians.

The normal domestic path is approval first, use second: a drug approved abroad must usually complete local trials and registration before it reaches a Chinese hospital, which takes years. Lecheng reverses the order — let clinically urgent patients use it first, accumulate evidence through use, then feed that evidence back into registration.

The price of the reversal is strict limitation: use only inside the zone, only at designated institutions, only for specific indications, and always under adverse-event monitoring and follow-up. It is not an open market; it is a fenced exception.

The patient experiences one dose. Behind it is a fixed administrative chain, and understanding it tells you how long to plan for.

• A medical institution in the zone files a clinically urgent import application with the record, prior treatment history and proof of overseas approval.
• The provincial health commission organises expert clinical review confirming urgency and the absence of an alternative.
• The provincial drug regulator approves; some products also require national filing.
• Use is restricted to the named institution and indication, with written informed consent.
• Adverse events are monitored and follow-up data reported as required.

Since 2019 the National Medical Products Administration has run a clinical real-world data pilot in Lecheng. The logic: these products already hold overseas registration and complete trial data, so real-world use in Lecheng can serve as supplementary evidence, reducing duplicate trials during domestic registration.

Several products have been approved through this route, covering ophthalmic implants, cardiovascular devices and some medicines. That is Lecheng's significance for regulatory reform nationwide — not only a place to be treated, but a place where evidence is produced.

For patients this means two things: the product carries both overseas registration data and domestic use data, and you become part of the data chain, so follow-up is not optional.

Several institutions operate in the zone with clearly different positioning. Confirm whether the institution has the specific product you need before choosing the hospital.

Institutions and departments change; confirm with the zone and hospital before travelling.

Lecheng solves access, not value for money. Three preconditions determine fit: no domestic alternative, a documented overseas treatment history, and willingness to self-pay and be followed up.

• Suits: rare disease or oncology needs with no domestic equivalent; patients who responded to a drug abroad and face interruption at home; need for the newest implantable devices not yet registered in China; ability to self-pay and comply with follow-up.
• Does not suit: expectations that every foreign drug is available; long inpatient rehabilitation; reliance on basic medical insurance; unstable conditions unsuitable for long travel.

Special-permit products and VIP services are market-priced and not covered by basic medical insurance. Budget five lines: product, inpatient and surgical fees, companion and accommodation, travel, and follow-up.

• Special-permit pricing usually references the overseas list price; some products cost more than in the country of origin.
• Medical services are billed at VIP or international department rates, not general clinic rates.
• A few commercial insurers offer direct billing, but pre-authorisation is required and unregistered products are frequently excluded.
• Treatment running longer than planned is normal; keep a 20–30% contingency.

There is an approval wait between submitting records and receiving treatment. Build it into your visa and flight planning.

• Send records, imaging, pathology and prior medication history remotely, in readable Chinese or English.
• The hospital assesses indication fit and whether the product is already available in the zone.
• The hospital applies to the province and waits for approval; days to weeks depending on product and completeness.
• Confirm the plan and a written quotation, then arrange visa and travel.
• Enter via Haikou, Sanya or Qionghai and register at the hospital.
• Treatment and inpatient observation, with informed consent and enrolment in follow-up.
• Discharge and follow-up; eligible oral medicines for chronic conditions may be taken out of the zone under the carry-out rules.

Hainan offers 30-day visa-free entry to citizens of 59 countries, limited to the province, and it is the simplest route to Lecheng. Other nationalities can use the 240-hour transit visa-free scheme, since Hainan is within the permitted area, or obtain an M (medical) visa.

One caveat: if the itinerary also includes Beijing, Shanghai or another province, the Hainan 59-country scheme does not apply and a visa valid nationwide is required.

Rumours about Lecheng travel faster than the policy itself. These five are the most common.

• That the special zone means any drug is available: it must be clinically urgent, approved abroad, and already introduced by the institution.
• That approved abroad means better than domestic options: for many indications a mature domestic regimen exists and the special route is neither faster nor better.
• That real-world data approval implies superior efficacy: it means the evidence was accepted, not that outcomes beat a comparator.
• That 30-day visa-free means long-term residence: overstaying is unlawful; long treatment needs a matching visa.
• That it is cheaper than the country of origin: with service fees some products cost more; obtain a written quotation first.

Lecheng opens a narrow door for patients with no domestic option. It is not a default first choice, but for a defined group — documented overseas use, no domestic alternative, able to self-pay and be followed up — it is currently the most realistic route inside China.

For most common conditions and for complex surgery that depends on high volume, tertiary hospitals in first-tier cities remain more dependable for both outcomes and follow-up. Read it alongside the Boao Super Hospital profile, the oncology specialty ranking and costs.